Strongyloidiasis natural history, complications and prognosis
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis natural history, complications and prognosis |
|
FDA on Strongyloidiasis natural history, complications and prognosis |
|
CDC on Strongyloidiasis natural history, complications and prognosis |
|
Strongyloidiasis natural history, complications and prognosis in the news |
|
Blogs on Strongyloidiasis natural history, complications and prognosis |
|
Risk calculators and risk factors for Strongyloidiasis natural history, complications and prognosis |
Overview
If left untreated, subclinical strongyloidiasis can disseminate and transform into hyperinfection syndrome, which has a mortality rate of 90%. Complications that can develop as a result of strongyloidiasis are disseminated strongyloidiasis, especially in patients with HIV or an otherwise weakened immune system, eosinophilic pneumonia and malnutrition due to problems absorbing nutrients from the gastrointestinal tract (malabsorption). With good treatment, people should make a full recovery. Often Sometimes treatment needs to be repeated. Infections that are severe or widespread often have a poor outcome, especially in people with a weakened immune system.[1]
Natural history
If left untreated, the subclinical strongyloidiasis can disseminate and transform into hyper-infection syndrome with a mortality rate of 90%.
Complications
Complications that can develop as a result of strongyloidiasis are:
- Disseminated strongyloidiasis, especially in patients with HIV or who are otherwise immunosuppressed
- Eosinophilic pneumonia
- Malnutrition due to problems absorbing nutrients from the gastrointestinal tract (malabsorption)
Prognosis
With appropriate treatment, people should make a full recovery. Sometimes, treatment needs to be repeated. Infections that are severe or widespread often have a poor outcome, especially in people with immunosuppression. Strongyloidiasis could be severe and life-threatening in specific groups including:
- Those who use of oral or intravenous steroids, for example, in patients with asthma, chronic obstructive pulmonary disease (COPD) exacerbations, lupus, gout, or in persons using steroids for immunosuppression or symptomatic relief
- Those with HTLV-1 infection
- Those with Hematologic malignancies such as leukemia or lymphoma
- Transplant recipients
Even with treatment, disseminated strongyloidiasis and hyperinfection syndrome have a mortality rate of 90%.
References
- ↑ Beknazarova M, Whiley H, Ross K (2016). "Strongyloidiasis: A Disease of Socioeconomic Disadvantage". Int J Environ Res Public Health. 13 (5). doi:10.3390/ijerph13050517. PMC 4881142. PMID 27213420.